Intangible Assets, Net |
12 Months Ended | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | |||||||||||||||||||||||||||||||||||||
| Intangible Assets, Net [Abstract] | |||||||||||||||||||||||||||||||||||||
| INTANGIBLE ASSETS, NET | NOTE 8 — INTANGIBLE ASSETS, NET
Net intangible assets consist of the following:
On November 5, 2024, the Company purchased a license of pharmaceutical distribution in Mainland China through its acquisition of 100% equity interest in Hupan Pharmaceutical. The Company recognized the distribution license as an intangible asset of $418,867 based on the assessment of fair value at the purchase date, adjusted by deferred taxes impact on temporary tax differences in an asset acquisition using the simultaneous equations method. The transaction was closed on November 21, 2024. impairment expense was recognized for the year ended June 30, 2026.
For the years ended June 30, 2026 and 2025, the Company recorded amortization expense of $85,484 and $53,427, respectively. |
||||||||||||||||||||||||||||||||||||